December 12, 2017
Zoetis today announced the launch of Vanguard ® CIV H3N2/H3N8, the latest vaccine in the company’s canine influenza virus (CIV) portfolio. The new bivalent vaccine helps protect dogs against two strains of the virus known to be circulating in the U.S., CIV H3N2 and CIV H3N8. CIV is a severe and highly contagious respiratory infection that has caused many serious disease outbreaks in 38 states across the country. 1 The United States Department of Agriculture (USDA) granted Zoetis a license for this vaccine in June 2017. “Zoetis is committed to helping protect dogs from all known strains of canine influenza virus, and our new Vanguard CIV H3N2/H3N8 vaccine is the most recent example of our innovation in this area,” said Tara L. Bidgood, DVM, PhD, DACVCP, Executive Director, U.S. Companion Animal Division Veterinary Professional Services at Zoetis. “We are pleased to offer veterinarians this vaccine, which is backed by outstanding safety and efficacy data, so that they can help protect
...
April 26, 2017
The first monoclonal antibody authorized for veterinary use in the European Union A single injection of Cytopoint treats the clinical signs of atopic dermatitis in dogs, including itch and inflammation, for up to one month Targets and neutralizes canine interleukin-31 (cIL-31), a key cytokine involved in stimulating itch in dogs with atopic dermatitis Joins Zoetis’ Apoquel ® (oclacitinib tablet), giving veterinarians two targeted treatment options for canine patients with atopic dermatitis Zoetis Inc . (NYSE:ZTS) today announced that the European Commission has granted the company marketing authorization for Cytopoint (lokivetmab), the first monoclonal antibody (mAb) therapy approved in the European Union for veterinary use. Cytopoint is indicated to treat the clinical signs, including itching and inflammation, associated with atopic dermatitis in dogs of any age weighing 3 kilograms or more. Cytopoint targets and neutralizes canine interleukin-31 (cIL-31), a key protein involved in
...
April 5, 2017
Zoetis launches Itch Instinct tool in support of its K-9 Courage™ Program Zoetis Inc. (NYSE:ZTS), the leading global animal health company, today announced that music and television star Nick Lachey* is teaming up with the company to launch Your Animal Instinct , a program to help your dog put its best paw forward this spring. Your Animal Instinct aims to help pet owners understand when their dog’s itching may be due to an allergy-related skin condition – and what they can do about it. During the program’s kick-off this spring allergy season, dog owners are encouraged to take an online itch quiz at YourAnimalInstinct.com to help them distinguish between their dog’s normal itch and when frequent scratching, licking, biting, and/or rubbing could be the sign of allergic skin disease. Completion of the “Itch Instinct” quiz will trigger a donation made by Zoetis to expand the number of recipients in its K-9 Courage™ Program, which provides healthcare assistance to retired military and
...
February 15, 2017
A new topical parasiticide for cats combines the active ingredient in Stronghold – selamectin – with sarolaner for broadened and extended spectrum of protection Company introduces first combination product building on its sarolaner platform in the $4.2 billion companion animal parasiticide market Zoetis Inc . (NYSE:ZTS) today announced that the European Commission has granted the company a license for Stronghold ® Plus (selamectin/sarolaner), a topical combination of parasiticides that treats ticks, fleas, ear mites, lice and gastrointestinal nematodes and prevents heartworm disease in cats. Veterinarians across the European Union now have a treatment choice that leverages the benefits of sarolaner, a new innovation in the class of isoxazolines, without sacrificing the broad spectrum protection, safety or ease of use they expect. ”The approval of Stronghold Plus enables Zoetis to offer veterinarians a new topical choice that treats the parasites commonly presenting a threat to cats
...